Ocumension Therapeutics
歐康維視生物
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1477)

VOLUNTARY ANNOUNCEMENT
CDE APPROVAL RECEIVED FOR A PHASE III CLINICAL TRIAL OF OT-703 IN CHINA

This announcement is made by Ocumension Therapeutics (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.

The board (the "**Board**") of directors of the Company is pleased to announce that the investigational new drug (IND) application for OT-703 (fluocinolone intravitreal implant), an injectable, non-biodegradable fluocinolone acetate intravitreal implant for the treatment of diabetic macular edema (DME), has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of the People's Republic of China to conduct a randomized, double-blind, parallel-controlled, multi-center phase III clinical trial to compare the safety and efficacy of 0.19 mg fluocinolone intravitreal implant with ranibizumab injection on the treatment of DME in China.

OT-703, namely the 190 microgram fluocinolone acetonide intravitreal implant in applicator (0.19 mg), is an injectable, non-biodegradable fluocinolone acetate intravitreal implant and used for treatment of DME by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. It has received the regulatory approval from the United States Food and Drug Administration (FDA) and marketed under the trade name "ILUVIEN®". It is the only FDA-approved corticosteroid intraocular implant for the treatment of DME with a three-year sustained-release period. In April 2021, the Company and Alimera Sciences, Inc. ("**Alimera**") entered into an exclusive license agreement, pursuant to which the Company obtained the exclusive licensed rights from Alimera in relation to the development and commercialization of ILUVIEN® in Greater China, South Korea and 11 countries in Southeast Asia.

Cautionary Statement: The Company cannot guarantee that it will ultimately commercialize OT-703 successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, June 9, 2022

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive directors.